Saccharomyces boulardii is a probiotic yeast with the strongest clinical evidence base for antibiotic-associated gut disruption of any probiotic strain. A 2017 Cochrane systematic review of 82 randomised controlled trials found it significantly reduces the risk of antibiotic-associated diarrhoea. The reason it outperforms bacterial probiotics in this specific context is straightforward: antibiotics do not kill it. Being a yeast rather than a bacterium gives it a fundamentally different cell wall structure that is unaffected by antibacterial drugs.
What Saccharomyces boulardii actually is
Most people assume all probiotics are bacteria. Saccharomyces boulardii is not. It is a yeast, taxonomically related to Saccharomyces cerevisiae, the same species used in bread-making and brewing. The specific strain used in clinical and therapeutic contexts was first isolated in 1923 by French scientist Henri Boulard from the skin of lychees and mangosteens in Southeast Asia, where he observed local people chewing the fruit to manage gut symptoms during a cholera outbreak.
The fact that it is a yeast has one enormous practical consequence: antibacterial antibiotics have no effect on it. Every antibiotic you take works by targeting bacterial structures, bacterial protein synthesis, or bacterial cell wall construction. Yeast cells have none of these targets. When you take a penicillin, a fluoroquinolone, or a macrolide, the S. boulardii in your gut is completely unaffected. This is why it can be taken concurrently with an antibiotic course, something most probiotic bacteria cannot do effectively.
The clinical evidence base
The 2017 Cochrane systematic review by Goldenberg and colleagues is the most comprehensive analysis of S. boulardii for antibiotic-associated diarrhoea and the most cited piece of evidence in this area. Cochrane reviews are considered the gold standard of clinical evidence because they pool and critically appraise all available randomised controlled trials rather than relying on individual studies that may have small samples or methodological weaknesses.
The review analysed 82 randomised controlled trials involving over 11,000 participants. The findings across the pooled analysis showed that S. boulardii supplementation produced a statistically significant reduction in the risk of antibiotic-associated diarrhoea compared to placebo. The risk ratio was approximately 0.52, meaning people taking S. boulardii had roughly half the risk of developing antibiotic-associated diarrhoea compared to those taking a placebo. This is a substantial effect size by clinical standards.
Importantly, the effect was consistent across different antibiotic types, different patient populations, and different durations of supplementation. It was not driven by one or two outlier trials. The consistency across 82 independent studies is what gives the evidence its strength.
The World Gastroenterology Organisation (WGO) 2023 Global Guidelines on Probiotics and Prebiotics list S. boulardii as a Grade A evidence strain specifically for antibiotic-associated diarrhoea prevention and treatment. Grade A in the WGO framework means consistent level one evidence from randomised controlled trials and systematic reviews. Very few probiotic strains achieve Grade A designation for any indication.
How it actually works in the gut
Understanding the mechanism matters because it explains why S. boulardii is useful for post-antibiotic recovery specifically, not just as a general probiotic.
Competitive exclusion during the vulnerable window
When antibiotics deplete the gut microbiome, the intestinal receptor sites that beneficial bacteria normally occupy become available. This creates a window of vulnerability during which opportunistic pathogens, including Clostridioides difficile, can establish themselves. S. boulardii occupies these receptor sites during the post-antibiotic period, not by colonising permanently (it does not), but by transiently blocking them until the recovering microbiome can re-establish. Studies using colonoscopy and intestinal biopsy have confirmed its presence in the intestinal mucosa during supplementation and its clearance after supplementation stops.
Immune modulation
S. boulardii interacts with the gut-associated lymphoid tissue, the immune infrastructure that lines the intestinal wall. It stimulates secretory IgA production, which is the primary immune defence of the intestinal mucosa. After antibiotics, this mucosal immune function is reduced. S. boulardii helps restore it faster than the microbiome recovers on its own.
Protease secretion
It secretes a protease enzyme that cleaves toxins produced by pathogenic bacteria. This is particularly relevant for C. difficile, whose toxins A and B are the primary cause of the severe antibiotic-associated colitis that can occasionally follow broad-spectrum antibiotic use. The protease activity provides a direct detoxification mechanism independent of the immune response.
Intestinal permeability reduction
Antibiotics increase intestinal permeability, the condition sometimes called leaky gut, where the tight junctions between intestinal cells loosen and allow substances to pass through the gut wall that should not. S. boulardii has been shown in multiple studies to restore these tight junctions and reduce permeability back toward baseline. This addresses one of the structural consequences of antibiotic treatment that bacterial probiotics do not specifically target.
Why timing matters: start at the end of the course, not weeks later
The clinical trials that show the strongest outcomes for S. boulardii consistently start supplementation either concurrently with the antibiotic course or immediately after it ends. Studies that start supplementation weeks after the course consistently show weaker effects.
The biological reason is the competitive exclusion mechanism described above. The post-antibiotic window is when the intestinal receptor sites are most available and when competition from the recovering microbiome is lowest. Starting S. boulardii on day one after finishing the course puts it in the gut at the optimal moment to occupy those sites. Waiting two weeks means the spontaneous recovery process has already begun, potentially in a direction that is harder to influence.
The dose used in clinical trials
The dosing range across the 82 Cochrane trials varied, but the most consistently effective doses were in the range of 4 to 10 billion colony forming units (CFU) per day, typically administered twice daily. The Aegis Protocol AM Shield capsule contains 5 billion CFU of lyophilised S. boulardii per dose, within the range shown to produce the outcomes in the clinical literature.
Lyophilisation, or freeze-drying, is the preservation method that produces the most stable and viable probiotic cells. Lyophilised S. boulardii maintains viability at ambient temperatures, which matters enormously in Indian conditions where cold chain reliability varies significantly. This is why the formulation uses lyophilised cells rather than fresh culture formats.
The delivery question
S. boulardii has better natural acid tolerance than bacterial probiotics due to its yeast cell wall structure. However, delivering it in delayed release capsules still produces meaningfully higher intestinal delivery than standard capsule formats. The stomach maintains a pH of 1.5 to 3.5 during active digestion, and even acid-tolerant organisms lose viability at these levels over time.
Delayed release HPMC capsules are designed to remain intact through the stomach environment and dissolve only when they reach the higher pH of the small intestine (pH 6 to 7.4). This is the delivery format used in the highest-quality clinical trials and the format the Aegis Protocol uses for precisely this reason.
Safety profile
S. boulardii has an excellent safety record across the clinical literature. The 82 Cochrane trials reported no serious adverse events attributable to the intervention. Minor side effects such as bloating and gas were occasionally reported and were transient.
The one contraindication worth being aware of: S. boulardii should not be used in people with central venous catheters, severely immunocompromised individuals, or those with known yeast allergies. For the vast majority of healthy adults recovering from a standard antibiotic course, none of these apply.
Free resource
The 14-Day Post-Antibiotic Recovery Guide
Covers the full science behind each ingredient, the AM/PM protocol structure, and what to expect each day during recovery.
Read the guide →The summary
S. boulardii's position as the most evidenced probiotic for post-antibiotic recovery comes from its unique biological status as a yeast combined with an unusually large and consistent clinical evidence base. It works during and immediately after antibiotic courses when bacterial probiotics cannot. It addresses multiple mechanisms of antibiotic gut damage simultaneously. And it has a Grade A WGO designation that very few probiotic strains achieve for any indication.
The reason it is the first ingredient in the Aegis Protocol AM Shield is because the evidence for it is stronger than for any other single probiotic intervention in the post-antibiotic context. Everything else in the formulation complements it. Nothing replaces it.